Radiation Therapy Planning AI Market Report 2026

The radiation therapy planning artificial intelligence (AI) market size has grown exponentially in recent years. It will grow from $1.45 billion in 2025 to $1.79 billion in 2026 at a compound annual growth rate (CAGR) of 23.9%. The growth in the historic period can be attributed to increasing adoption of ai-based radiotherapy solutions, growing demand for personalized cancer treatment, rising use of automation in radiation planning, expansion of oncology centers in developed regions and increasing focus on improving treatment accuracy.

The radiation therapy planning artificial intelligence (AI) market size is expected to see exponential growth in the next few years. It will grow to $4.18 billion in 2030 at a compound annual growth rate (CAGR) of 23.6%. The growth in the forecast period can be attributed to growing integration of cloud-based ai platforms, increasing investment in healthcare digitalization, rising demand for multi-cancer ai planning tools, expansion of research and development in oncology ai and increasing adoption in emerging markets. Major trends in the forecast period include technological advancements in ai-driven contouring and dose calculation, innovations in cloud-based radiation therapy platforms, development of predictive modeling for treatment outcomes, research and development in adaptive radiotherapy and technological advancements in workflow automation and quality assurance.

The increasing emphasis on personalized and precision radiation therapy is expected to drive the growth of the radiation therapy planning artificial intelligence (AI) market in the coming years. Personalized and precision radiation therapy involves customizing radiation dose, delivery techniques, and treatment plans according to a patient’s specific tumor characteristics and anatomy. This focus is growing as clinicians aim to maximize tumor control while minimizing damage to surrounding healthy tissue by tailoring dose, targeting, and timing to individual tumor biology. Radiation therapy planning AI supports this approach by providing automated tools that generate optimized, patient-specific treatment plans more quickly and consistently than traditional manual methods. For example, in May 2024, the UK Department for Health and Social Care reported that all National Health Service radiotherapy departments in England received artificial intelligence technology through £15.5 million in government funding. The technology automatically reviews scans to distinguish cancerous cells from healthy organs 2.5 times faster than previous methods, reflecting the increasing adoption of precision radiotherapy techniques. Consequently, the rising focus on personalized and precision radiation therapy is fueling the growth of the radiation therapy planning AI market.

Major companies in the radiation therapy planning artificial intelligence (AI) market are concentrating on creating advanced solutions, such as AI-powered automation and integrated tools, to improve precision, increase clinical efficiency, and reduce manual planning time. AI-powered automation and integrated tools involve sophisticated algorithms that simplify complex treatment planning processes, minimizing user input and variability. For example, in July 2024, RaySearch Laboratories AB, a Sweden-based medical technology company, introduced the RayStation 2024B treatment planning system. This comprehensive platform features advanced AI-based auto-contouring and a new Proton Monte Carlo dose calculation engine for exceptional accuracy. It offers automated tools for adaptive therapy and plan optimization, allowing smooth integration of MR-Linac workflows and efficient proton beam therapy planning with minimal manual effort. The system also includes enhanced scripting and module integration, increasing versatility and reducing operational complexity for oncology clinics and research centers.

In May 2024, Radformation Inc., a US-based provider of automation software and clinical workflow solutions for cancer care, acquired Limbus AI for an undisclosed amount. Through this acquisition, Radformation seeks to enhance its AI-driven radiation therapy offerings by incorporating advanced automatic contouring technology into its planning and automation portfolio, improving clinical efficiency and treatment plan accuracy. Limbus AI is a Canada-based company that provides machine learning-powered automatic contouring software designed to streamline workflows and increase efficiency in radiation therapy planning.

Major companies operating in the radiation therapy planning artificial intelligence (AI) market are Philips Healthcare, Siemens Healthineers AG, Elekta AB, Brainlab SE, Accuray Incorporated, RaySearch Laboratories AB, GE HealthCare, MVision AI, Spectra Medical India Pvt. Ltd., Coexya, LAP GmbH Laser Applikationen, Radformation Inc., TheraPanacea, DOSIsoft SA, Siris Medical Inc., Prowess Inc., Manteia Medical Technologies, Oncora Medical Inc., Adaptiiv Medical Technologies Inc., ViewRay Systems Inc., Pvmed Inc., Doctors App, Mirada Medical Ltd., Vision RT Ltd.

North America was the largest region in the radiation therapy planning artificial intelligence (AI) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radiation therapy planning artificial intelligence (AI) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiation therapy planning artificial intelligence (AI) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the radiation therapy planning ai market by increasing costs of imported gpus, high-performance computing hardware, medical imaging interfaces, and specialized servers required for ai deployment. cancer treatment centers in north america and europe are most affected due to reliance on imported advanced computing infrastructure, while asia-pacific faces higher costs for ai system integration. these tariffs are increasing capital expenditure and slowing adoption among smaller centers. however, they are also promoting local data center investments, domestic ai software development, and regional innovation in cost-efficient oncology planning solutions.

Radiation therapy planning artificial intelligence (AI) refers to AI-powered software designed to assist in creating optimized, precise, and personalized radiation treatment plans for cancer patients. It automates tasks such as contouring, dose calculation, and treatment optimization to enhance accuracy and efficiency. These systems improve clinical outcomes by reducing planning time and minimizing human error.

The primary components of radiation therapy planning artificial intelligence solutions are software, hardware, and services. Software consists of AI-driven planning platforms that automate contouring, dose calculation, and treatment plan optimization to improve precision and efficiency in radiation therapy workflows. These solutions are based on technologies such as machine learning, deep learning, and knowledge-based planning, deployed through on-premises and cloud-based models, used in applications including breast cancer, lung cancer, prostate cancer, head and neck cancer, and others, among end users such as hospitals, cancer treatment centers, research institutes, and others.

The radiation therapy planning artificial intelligence (AI) market consists of revenues earned by entities by providing services such as AI-based treatment plan generation, dose optimization, image segmentation, tumor contouring, adaptive radiotherapy guidance, workflow automation, and clinical decision support. The market value includes the value of related goods sold by the service provider or included within the service offering. The radiation therapy planning artificial intelligence (AI) market includes sales of AI-based treatment planning software, image segmentation and contouring tools, dose calculation and optimization platforms, adaptive radiotherapy solutions, and integrated AI-enabled oncology workflow systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.